Sertraline

Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Author(s): 
Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
Journal of Psychopharmacology (Oxford, England)

We describe a patient with depression who was well controlled with sertraline monotherapy developing two relapses of depression in close temporal relationship with starting ayurvedic herbal mixtures. We discuss the possibility of a pharmacokinetic herb-drug interaction decreasing the therapeutic efficacy of sertraline leading to the relapses of depression. We speculate the herbal plant most likely to be responsible for this interaction is either Terminalia chebula or Commiphora wighteii.

Author(s): 
Prasad, K. P. R. C.
Tharangani, P. G. D.
Samaranayake, C. N.
Publication Title: 
Depression and Anxiety

BACKGROUND: Scant research has examined the effect of neuropsychological (NP) functioning on treatment outcome in pediatric obsessive-compulsive disorder (OCD). This study sought to address this gap in existing research. METHODS: A total of 63 youths were included in this study and asked to complete the Rey-Osterrieth Complex Figure (ROCF) and specific subtests of the Wechsler Intelligence Scale for Children, Third Edition (WISC-III).

Author(s): 
Flessner, Christopher A.
Allgair, Amy
Garcia, Abbe
Freeman, Jennifer
Sapyta, Jeffrey
Franklin, Martin E.
Foa, Edna
March, John
Publication Title: 
Molecular Psychiatry

Telomeres are DNA-protein complexes that cap linear DNA strands, protecting DNA from damage. When telomeres critically shorten, cells become susceptible to senescence and apoptosis. Telomerase, a cellular ribonucleoprotein enzyme, rebuilds the length of telomeres and promotes cellular viability. Leukocyte telomeres are reportedly shortened in major depression, but telomerase activity in depression has not been previously reported.

Author(s): 
Wolkowitz, O. M.
Mellon, S. H.
Epel, E. S.
Lin, J.
Reus, V. I.
Rosser, R.
Burke, H.
Compagnone, M.
Nelson, J. C.
Dhabhar, F. S.
Blackburn, E. H.
Publication Title: 
Progress in Neuro-Psychopharmacology & Biological Psychiatry

OBJECTIVES: The "neurotrophin hypothesis" of depression posits a role of brain-derived neurotrophic factor (BDNF) in depression, although it is unknown whether BDNF is more involved in the etiology of depression or in the mechanism of action of antidepressants. It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response. METHODS: Thirty un-medicated depressed subjects were treated with escitalopram (N=16) or sertraline (N=14) for 8 weeks. Twenty-five of the depressed subjects completed 8 weeks of antidepressant treatment and had analyzable data.

Author(s): 
Wolkowitz, Owen M.
Wolf, Jessica
Shelly, Wendy
Rosser, Rebecca
Burke, Heather M.
Lerner, George K.
Reus, Victor I.
Nelson, J. Craig
Epel, Elissa S.
Mellon, Synthia H.
Publication Title: 
Brain, Behavior, and Immunity

Chronic inflammation and oxidative stress have been implicated in the pathophysiology of Major Depressive Disorder (MDD), as well as in a number of chronic medical conditions. The aim of this study was to examine the relationship between peripheral inflammatory and oxidative stress markers in un-medicated subjects with MDD compared to non-depressed healthy controls and compared to subjects with MDD after antidepressant treatment. We examined the relationships between IL-6, IL-10, and the IL-6/IL-10 inflammatory ratio vs.

Author(s): 
Rawdin, B. J.
Mellon, S. H.
Dhabhar, F. S.
Epel, E. S.
Puterman, E.
Su, Y.
Burke, H. M.
Reus, V. I.
Rosser, R.
Hamilton, S. P.
Nelson, J. C.
Wolkowitz, O. M.
Publication Title: 
Molecular Psychiatry

Telomeres are DNA-protein complexes that cap linear DNA strands, protecting DNA from damage. When telomeres critically shorten, cells become susceptible to senescence and apoptosis. Telomerase, a cellular ribonucleoprotein enzyme, rebuilds the length of telomeres and promotes cellular viability. Leukocyte telomeres are reportedly shortened in major depression, but telomerase activity in depression has not been previously reported.

Author(s): 
Wolkowitz, O. M.
Mellon, S. H.
Epel, E. S.
Lin, J.
Reus, V. I.
Rosser, R.
Burke, H.
Compagnone, M.
Nelson, J. C.
Dhabhar, F. S.
Blackburn, E. H.
Publication Title: 
Oncotarget

To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications.

Author(s): 
Kast, Richard E.
Boockvar, John A.
Brüning, Ansgar
Cappello, Francesco
Chang, Wen-Wei
Cvek, Boris
Dou, Q. Ping
Duenas-Gonzalez, Alfonso
Efferth, Thomas
Focosi, Daniele
Ghaffari, Seyed H.
Karpel-Massler, Georg
Ketola, Kirsi
Khoshnevisan, Alireza
Keizman, Daniel
Magné, Nicolas
Marosi, Christine
McDonald, Kerrie
Muñoz, Miguel
Paranjpe, Ameya
Pourgholami, Mohammad H.
Sardi, Iacopo
Sella, Avishay
Srivenugopal, Kalkunte S.
Tuccori, Marco
Wang, Weiguang
Wirtz, Christian R.
Halatsch, Marc-Eric
Publication Title: 
Oncotarget

CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs--aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one or more important growth-enhancing pathways used by glioblastoma. By blocking survival paths, the aim is to render temozolomide, the current standard cytotoxic drug used in primary glioblastoma treatment, more effective.

Author(s): 
Kast, Richard E.
Karpel-Massler, Georg
Halatsch, Marc-Eric
Publication Title: 
Journal of Psychopharmacology (Oxford, England)

We describe a patient with depression who was well controlled with sertraline monotherapy developing two relapses of depression in close temporal relationship with starting ayurvedic herbal mixtures. We discuss the possibility of a pharmacokinetic herb-drug interaction decreasing the therapeutic efficacy of sertraline leading to the relapses of depression. We speculate the herbal plant most likely to be responsible for this interaction is either Terminalia chebula or Commiphora wighteii.

Author(s): 
Prasad, K. P. R. C.
Tharangani, P. G. D.
Samaranayake, C. N.
Subscribe to RSS - Sertraline